GeneScience Pharmaceuticals Co., Ltd.   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Changchun China (1996)
Status: No NME R&D (1996)

Organization Overview

First Clinical Trial
2006
NCT01342146
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Changchun GeneScience Pharmaceutical Co., Ltd. | GeneScience Pharmaceuticals Co., Ltd.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anovulation (Phase 3)

Arthritis, Juvenile (Phase 1)

Burns (Phase 4)

Dwarfism (Phase 4)

Dwarfism, Pituitary (Phase 4)

Endocrine System Diseases (Phase 4)

Gonadal Dysgenesis (Phase 2)

Kidney Diseases (Phase 3)

Ovarian Hyperstimulation Syndrome (Phase 3)

Prader-Willi Syndrome (Phase 3)

Recurrence (Phase 1)

Renal Insufficiency, Chronic (Phase 3)

Syndrome (Phase 3)

Turner Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 49
  • # of Trial APIs: 20